With a well-established infrastructure that spans the entire pharma value chain from APIs to manufacturing, Switzerland is uniquely positioned to become a specialized hub for the most promising area of advanced medicine — cell and gene therapies.
Friday, December 13, 2024
The industry stays on track with FDA approvals for cell and gene therapies
Monday, November 25, 2024
How flexible rapid testing can serve the different needs of cell and gene therapy manufacturers
Friday, November 22, 2024
By continuing to crack the code of complex manufacturing, we can move closer to making long-lasting treatments affordable and available to all
Friday, November 22, 2024
Generating an analytical strategic plan and developing methods appropriately during process development will help ensure quality, safety and efficacy
Wednesday, November 20, 2024
Autologous CAR-T cell therapies have already proven effective in treating hematological cancers, spurring extensive research into their potential for a wider range of diseases.
Wednesday, November 20, 2024
For the successful delivery of functional genes to patients, recombinant adenoviral-associated vectors (AAVs) are the most established and leading platform for rare and severe human diseases.
Wednesday, November 20, 2024
The limitations of current preservation approaches are driving researchers toward new alternatives
Wednesday, November 06, 2024
Facilities that make cell and gene therapies require cleaning and disinfection strategies not found at other drug manufacturing sites
Wednesday, November 06, 2024
Evaluating the factors that would support or preclude the birth and expansion of biosimilar versions of CAR-T therapies
Thursday, October 31, 2024